Our flagship products are elaborations of amino acid technology and are directly related to the evolution of total parenteral nutrition (TPN) which has become a standard of care during the past forty years.

Myogence was developed as a derivative of ongoing research into the anti-atherosclerosis product, Atheromine, which was an extension of Dr. Dudrick’s initial discovery and advancement of the TPN science. The relationship of the two products underscores the promise of the root nutritional methodology based on amino acids. Patients suffering from diabetes, HIV/AIDS, hepatitis, Crohn’s disease, and various cancers represent challenges to nutritional and metabolic well being. GHPC’s products are designed to improve survival, recovery and quality of life.

Amino acids are the fundamental “building blocks” of proteins. In pursuing optimal cellular performance, GHPC recognizes the body as a complex aggregation and integration of numerous synergistic components. Each one performs specific individual primary and secondary functions. However, nutrients like vitamins, minerals, fats and carbohydrates alone or even in combination may or may not yield optimal performance. Clearly the use of amino acids provides the best mechanism for introducing energy into the body’s metabolic processes.

1.) MYOGENCEsignificantly increases muscular work capacity. It is the only amino acid formula granted U.S. Patent (#5,026,721) for “enhanced physical performance.” An off-shoot of the Atheromine cardiovascular research, the Myogence studies were originally intended to develop nutritional alternatives to anabolic steroids for elite athlete populations in response to their demand for safe and effective products. Myogence study has demonstrated substantial improvement in such athletes in both strength and stamina of up to 60% and 90%, respectively (see Appendix III on “Myogence”). This is in favorable contrast to anabolic steroids, which have been demonstrated to stimulate no more than 7% improvement in performance in elite or amateur athletes, at the expense of their long-term health and well-being. Its consumption has demonstrated efficacy in strenuous exercise or work activities, has improved “recovery” and has not been accompanied or followed by the undesirable and uncomfortable “side” or “after” effects commonly associated with the ingestion of sugar, caffeine and herbal extracts.

Myogence consumption by the average person improves strength, stamina, energy, activity, and productivity. As a result of the obviously increasing interest in, and utilization of, performance enhancing nutritional products by the general population, Myogence can capture 10% of the $50B/yr U.S. nutritional supplement market within 2 to 4 years with effective marketing, sales and distribution supply chains. Conservative estimates target capturing 7-8% of the $300B/yr Global “energy product” market, which currently is dominated by products featuring ingredients such as anabolic steroids/sterols, hormones, sugar and caffeine, all of which are accompanied by undesirable and even potentially dangerous secondary actions and effects.

Delivered orally, Myogence provides a special formulation of the most biologically active amino acids, blended with additional polypeptides and proteins to create a balanced “whole profile.” The base formula of Myogence presents potential for development of at least twelve secondary product lines specifically formulated for various demographics. Alternatively, Myogence can also be delivered in the form of “bars,” “shakes” and other enriched over-the-counter “food” products. Myogence consumption by clinically-diseased, nutritionally-deprived and/or disordered health populations has been very well received and utilized, indicating “excellent” opportunities for Myogence product line derivatives. These derivative products will be eligible to qualify for insurance reimbursement of approximately $60 per month under current U.S. guidelines.

Myogence fortifies bodily activity and demand for strength and stamina by providing the preferred body fuel for muscular activity and recovery. Its development was inspired by recognition of the dangers presented by commonly used ergogenic agents. Initial studies of Myogence use demonstrated that cardiovascular performance was a key factor in both strength and conditioning training for power, intensity and duration. Preliminary work to date indicates that Myogence enhanced nutrition may modulate the metabolism and/or increase the efficiency of the metabolic energy pathways of the liver.

Thus it may be an ideal candidate as an effective supplement to treatment regimens for HIV/AIDS, hepatitis, malaria, tuberculosis and multiple other diseases. The actual or specific metabolic pathway through which Myogence influences strength and stamina has not yet been definitively established, providing significant opportunity for future research, growth and development.

Furthermore, extensive use of Myogence has resulted in overwhelming reports of improved energy, activity, productivity, mental acuity and overall sense of well being, including personal effectiveness and morale. It provides a low-cost, non-pharmacologic, natural and wholesome nutritional alternative to market standard sugar and stimulant-rich, performance-enhancing products. A partial list of its potential benefits are:

MARKET DESCRIPTION AND BENEFITS OF MYOGENCE:

• Amino acids are the best means for introducing and sustaining optimal body energy.

• Consumers will pay for a safe, effective “crash-free” energy boost.

• Athletes want a true and legal edge in performance, and they will pay for it.

• Myogence can improve strength, mobility and activities of daily living in the geriatric population.

• Myogence can help ease the adverse effects of x-ray therapy and chemotherapy in cancer patients.

• Myogence is a safe alternative to dangerous anabolic steroids, their “masking” agents, and hormones for building body mass and improving stamina. • It is safe for most populations including teenage athletes.

• Patients will pay for a faster, safer and better way to rebuild strength after surgery and serious illness.

• Myogence can be specially formulated and targeted for all age groups and various medical conditions.

• Myogence can be added to other products to enhance or complement them.

• Myogence is the only, patented and scientifically proven amino acid performance formula on the market.

• A dozen or more applications can be prepared by the second year of operation, ready to be marketed by year three.

2.) ATHEROMINEis a second generation, safe Total Parenteral Nutrition (TPN) technology designed to induce the reduction of total and “bad” cholesterol and the regression of atherosclerosis (U.S. Patent #5,032,608).

Developed by Dr. Dudrick, a leader in clinical nutritional intervention for over 40 years and recognized worldwide as “the father of” TPN, Atheromine features a specific amino acid profile delivered via central venous catheter. The IV delivery required extensive pre-clinical and FDA mandated Clinical Trials as they existed when carried out twenty years ago.

Atheromine is a viable treatment for at least 10% of the estimated $50 Billion per year U.S. CVD population who can not be helped by, or have not responded favorably to, conventional therapies. Atheromine has exhibited no indigenous adverse reactions other than those associated with TPN administration.

Furthermore, it is complementary to the current “standard of care” pharmaceutical and technical endovascular or surgical interventions. As an over-the-counter consumer treatment, oral forms of Atheromine are potential “Blockbuster” healthcare products worldwide.

The effective medical action involves modifying cholesterol metabolism. This results in lower LDL (bad cholesterol) and higher HDL (good cholesterol) blood levels. Improved myocardial perfusion has also been demonstrated with Atheromine administration, resulting in improved oxygenation of the heart muscle, stroke volume and coronary vascularization.

Because it can be applied to the treatment of over 70% of the U.S. CVD population, oral Atheromine will be promptly marketed GHPC. Additionally, we will advance the claim that, due to its added value, IV Atheromine should be administered as the amino acid formulation of choice for the vast majority of TPN solutions currently used worldwide.

Furthermore, the base formula of Atheromine can be customized or “tailored” to the individual requirements of patients with a wide variety of co-morbidities or collateral conditions.

Atheromine is mainly indicated for people in “Western” Countries whose diet contains fat-rich foods and who subsequently exhibit the effects of “excess fat consumption” on their arteries. It is recognized that the two market areas with the highest per capita incidence of atherosclerosis are North America and Europe.

Traditional diets that contain too much saturated fat overwhelm the body’s natural ability to cope, leading to high levels of LDL (bad cholesterol), secondary inflammation, and the subsequent build-up of plaque within the arteries. The dangerous cardiovascular consequences that follow are well known. Atheromine provides low cost, non-pharmacologic, natural and wholesome alternative cardiovascular therapy that does not manifest the discomforts and risks associated with conventional care.

In summary, Atheromine can be used either as a “stand alone” treatment or as an adjunct therapy for the management of atherosclerosis.